Share this video  

GU Cancers 2023 | Post-second-line systemic treatment for advanced RCC

Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, comments on post-second-line systemic treatment for advanced renal cell carcinoma, including with axitinib, everolimus, cabozantinib and tivozanib. Nivolumab is approved in refractory settings. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA,

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.